In This Article:
Investing.com -- Bernstein downgraded Tandem Diabetes Care (NASDAQ:TNDM) to Market-Perform from Outperform, citing market share losses and rising competition in the insulin pump space.
The firm also lowered its price target to $25 from $35.
Tandem's stock plunged 35% following its fourth-quarter earnings report, which showed weaker-than-expected margins and signs of market share erosion in U.S. type 1 diabetes pump starts.
Bernstein highlighted increased competitive pressure, particularly from Beta Bionics, as well as potential disruptions from the company’s sales realignment and distributor transition.
The firm cut its long-term revenue estimates, now projecting a 6.5% lower figure for 2027, pushing its EPS estimate into negative territory.
Bernstein reduced its price-to-sales multiple assumption to 1.5x, reflecting concerns over the company’s growth trajectory.
Related Articles
Bernstein downgrades Tandem Diabetes on market share loss concerns
JPMorgan downgrades Southwest on valuation concerns
Trump, TSMC CEO to announce new $100 billion US investment plans